Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor
Table 2
The cumulative distribution function of the QFM scores for each group.
Quantiles/interval values
HC
pMS
fMS
Quantiles
Min
2.03
0.76
1.06
p25
112.2
31.23
39.95
Median
228
144.8
130.5
p75
358.67
302
217.07
Max
1730.4
1307.6
1206.4
Cumulative distribution: frequencies (%)
<50
9 (10.5)
30 (31.3)
22 (28.2)
[50; 100)
17 (19.8)
39 (40.6)
32 (41.0)
[100; 150)
31 (36.0)
49 (51.0)
44 (56.4)
[150; 200)
36 (41.9)
53 (55.2)
53 (67.9)
[200; 250)
47 (54.7)
65 (67.7)
61 (78.2)
[250; 300)
55 (64.0)
71 (74.0)
65 (83.3)
[300; 350)
63 (73.3)
75 (78.1)
69 (88.5)
[350; 400)
72 (83.7)
79 (82.3)
72 (92.3)
>400
86 (100)
96 (100)
78 (100)
Note: This table shows cumulative distribution of the QFM scores. HC, healthy controls; pMS, progressive MS patients; fMS, MS patients treated with fingolimod; p25, lower quartile; p75, upper quartile.
